Clinical Trial Update: Pre- and Postoperative Use of ZD1839 (Iressa) in Recurrent Glioblastoma, Including Translational Research [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating pre- and postoperative use of ZD1839 (Iressa) in recurrent glioblastoma, with translational research components.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Iressa (gefitinib)

Snippet

Sponsor: University of Zurich | Conditions: Recurrent Glioblastoma | Phase 2 | Status: COMPLETED